Ftse Mib
34.937,72
-0,43%
DAX
20.137,61
-0,41%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
93.091,97
-1,48%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cocrystal Pharma Inc (COCP) Cocrystal Pharma Inc (COCP) Notizie

COCP

Cocrystal Pharma (COCP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:COCP
DataOraFonteTitoloSimboloCompagnia
08/01/202514:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COCPCocrystal Pharma Inc
08/01/202514:00GlobeNewswire Inc.Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral InfectionsNASDAQ:COCPCocrystal Pharma Inc
31/12/202414:00GlobeNewswire Inc.Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
13/11/202414:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:COCPCocrystal Pharma Inc
13/11/202414:00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
31/10/202413:00GlobeNewswire Inc.Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season BeginsNASDAQ:COCPCocrystal Pharma Inc
11/10/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:COCPCocrystal Pharma Inc
26/09/202414:00GlobeNewswire Inc.Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose CohortsNASDAQ:COCPCocrystal Pharma Inc
19/08/202422:05GlobeNewswire Inc.Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment ConferencesNASDAQ:COCPCocrystal Pharma Inc
14/08/202414:00GlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
18/07/202414:00GlobeNewswire Inc.Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease InhibitorNASDAQ:COCPCocrystal Pharma Inc
20/06/202414:00GlobeNewswire Inc.New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy CowsNASDAQ:COCPCocrystal Pharma Inc
13/05/202414:00GlobeNewswire Inc.Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
07/05/202422:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:COCPCocrystal Pharma Inc
01/05/202414:00GlobeNewswire Inc.Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal InfluenzaNASDAQ:COCPCocrystal Pharma Inc
28/03/202413:00GlobeNewswire Inc.Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
19/03/202413:00GlobeNewswire Inc.Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza ANASDAQ:COCPCocrystal Pharma Inc
04/01/202414:00GlobeNewswire Inc.Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational CandidatesNASDAQ:COCPCocrystal Pharma Inc
02/01/202415:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:COCPCocrystal Pharma Inc
06/12/202314:00GlobeNewswire Inc.Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza ANASDAQ:COCPCocrystal Pharma Inc
29/11/202314:00GlobeNewswire Inc.Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
27/11/202314:00GlobeNewswire Inc.Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:COCPCocrystal Pharma Inc
13/11/202314:00GlobeNewswire Inc.Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
09/11/202314:00GlobeNewswire Inc.Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West CoastNASDAQ:COCPCocrystal Pharma Inc
31/10/202313:00GlobeNewswire Inc.Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344NASDAQ:COCPCocrystal Pharma Inc
28/09/202314:00GlobeNewswire Inc.Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and CoronavirusNASDAQ:COCPCocrystal Pharma Inc
05/09/202314:00GlobeNewswire Inc.Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment ConferenceNASDAQ:COCPCocrystal Pharma Inc
14/08/202314:00GlobeNewswire Inc.Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsNASDAQ:COCPCocrystal Pharma Inc
08/08/202314:00GlobeNewswire Inc.Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus LeadNASDAQ:COCPCocrystal Pharma Inc
15/06/202322:58Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:COCPCocrystal Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:COCP

La tua Cronologia

BIT
STMMI
ST Microelectronics
BIT
ENEL
Enel
BIT
ISP
Intesa Sanpaolo
BIT
CPR
Davide Campari
BIT
ENI
Eni
BIT
UCG
Unicredit
BIT
BPE
Bper Banca
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
AMP
Amplifon
BIT
SRG
Snam
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network